ANSWER: C

Rationale:

Option C is correct. This case illustrates the consequence of failing to apply the mandatory pre-emptive tacrolimus dose reduction before initiating a potent CYP3A4-inhibiting azole. Tacrolimus is metabolized almost entirely by intestinal and hepatic CYP3A4; voriconazole's potent CYP3A4 inhibition simultaneously increases tacrolimus absorption from the gut and slows its hepatic elimination, producing an approximately 3- to 5-fold rise in tacrolimus area under the concentration-time curve. Without a proactive dose reduction, tacrolimus concentrations rise rapidly as voriconazole reaches its own steady state over two to three days — exactly as demonstrated by the jump from 7 ng/mL to 28 ng/mL by Day 3. A trough of 28 ng/mL is markedly supratherapeutic (most transplant centers target 5 to 15 ng/mL depending on time post-transplant and center protocol) and produces the classic triad of calcineurin inhibitor toxicity: nephrotoxicity (creatinine rise), neurotoxicity (tremor, headache), and potential for further deterioration if not corrected. The correct immediate management is to hold tacrolimus or reduce it dramatically, measure daily troughs until they return to the therapeutic range, and continue voriconazole at full dose for the aspergillosis. The error was the failure to reduce tacrolimus to approximately one-third of the current dose before the first voriconazole dose — the standard protocol for this interaction.

• Option A: Option A is incorrect; voriconazole does cause neurotoxicity at supratherapeutic concentrations, but in this case the primary cause of tremor and renal dysfunction is tacrolimus toxicity from the unmanaged CYP3A4 interaction — the clinical picture is consistent with calcineurin inhibitor toxicity, not voriconazole toxicity, and the tacrolimus trough of 28 ng/mL directly implicates tacrolimus as the cause.
• Option B: Option B is incorrect; invasive aspergillosis can cause hepatic involvement, but the acute and dramatic rise in tacrolimus trough to 28 ng/mL beginning within days of starting voriconazole is far more consistent with the expected pharmacokinetic interaction than with aspergillosis-driven hepatic dysfunction.
• Option D: Option D is incorrect; tacrolimus troughs can and do rise dramatically within two to three days of initiating a potent CYP3A4 inhibitor because CYP3A4 inhibition begins with the first voriconazole dose and reaches near-maximal effect as voriconazole approaches steady state; a four-fold rise in trough is precisely the expected pharmacokinetic outcome of this unmanaged interaction.
• Option E: Option E is incorrect; tacrolimus is not significantly renally eliminated — it is a high molecular weight lipophilic drug metabolized by CYP3A4 and excreted in bile; renal tubular secretion competition is not the mechanism of the tacrolimus-voriconazole interaction.

ANSWER: A

Rationale:

Option A is correct. This case demonstrates the clinical consequence of posaconazole oral suspension absorption failure during the high-risk neutropenic period. Two pharmacokinetic factors are acting simultaneously to reduce suspension absorption below the prophylaxis threshold. First, ranitidine is an H2 receptor antagonist — like proton pump inhibitors, it raises intragastric pH; posaconazole suspension requires acidic gastric conditions for optimal solubilization and dissolution, and acid suppression significantly reduces absorption. Second, the near-complete absence of fatty food intake deprives the suspension of the lipid-driven micellar incorporation mechanism that enables posaconazole's lymphatic absorption pathway; the suspension's bioavailability is markedly dependent on co-ingestion of a high-fat meal, and clear liquid intake provides essentially no lipid substrate for this process. Together, these two factors sustained subtherapeutic posaconazole exposure throughout the prophylaxis period, allowing Aspergillus fumigatus to establish invasive pulmonary infection. For treatment of the now-established aspergillosis, three changes are required: first, the posaconazole formulation must be switched — the delayed-release tablet bypasses gastric pH dependence and does not require fatty food, while intravenous posaconazole eliminates all absorption variability; second, the target trough shifts upward from the prophylaxis threshold of 0.7 mg/L to the treatment target of above 1.0 to 1.5 mg/L for mold infection; third, voriconazole is often preferred as primary treatment for confirmed aspergillosis, and the clinical team should consider whether posaconazole is the optimal treatment agent or whether voriconazole should be initiated.

• Option B: Option B is incorrect; a trough of 0.5 mg/L is below the prophylaxis target of 0.7 mg/L — it is not adequate, and the breakthrough is consistent with subtherapeutic exposure rather than intrinsic posaconazole non-activity; posaconazole does have activity against Aspergillus fumigatus.
• Option C: Option C is incorrect; while Aspergillus resistance to azoles does occur and should be tested, the immediately actionable explanation here is subtherapeutic posaconazole concentrations from documented absorption failure — addressing this is the priority, and TDM is directly relevant.
• Option D: Option D is incorrect; ranitidine is an H2 receptor antagonist and does not induce CYP3A4 — it impairs posaconazole suspension absorption through acid suppression, not through metabolic induction; doubling the suspension dose in this clinical context would be unlikely to achieve adequate concentrations given the ongoing absorption failure from pH and fat intake deficits.
• Option E: Option E is incorrect; mucositis-related poor oral intake and reduced gastrointestinal function does contribute to absorption failure, but the specific pharmacokinetic mechanisms — acid suppression and absent fat intake — can both be corrected by switching to the delayed-release tablet or intravenous formulation; this is not a situation where formulation change is futile.

ANSWER: E

Rationale:

Option E is correct. This case illustrates the warfarin-fluconazole interaction in a clinical context requiring balanced management of both the supratherapeutic INR and the ongoing antifungal treatment. Fluconazole inhibits CYP2C9, which metabolizes the pharmacologically active S-enantiomer of warfarin; this reduces S-warfarin clearance and elevates the INR — here from 2.4 to 5.8 over three weeks of co-administration. An INR of 5.8 in the absence of bleeding requires urgent correction but not emergency reversal: holding warfarin for one to two doses allows the INR to fall toward the therapeutic range, and rechecking within three to five days confirms the response. When warfarin is resumed, the dose should be reduced to reflect the inhibited S-warfarin clearance state that will persist for the remaining two weeks of fluconazole therapy. Fluconazole should not be discontinued prematurely — two weekly doses remain, the total course duration is short, and incomplete treatment of vaginal candidiasis risks recurrence or treatment failure. The interaction is entirely manageable with appropriate warfarin dose adjustment and monitoring without sacrificing the antifungal course. After fluconazole is completed, the CYP2C9 inhibition will resolve within days, warfarin clearance will normalize, and the warfarin dose will need to be increased back toward the original dose with INR monitoring.

• Option A: Option A is incorrect; intravenous vitamin K is reserved for INRs associated with serious or life-threatening bleeding or for INRs substantially above 10 in high-risk patients — an INR of 5.8 without bleeding does not require intravenous vitamin K or emergency reversal; holding doses and monitoring is appropriate.
• Option B: Option B is incorrect; an INR of 5.8 is supratherapeutic and significantly increases bleeding risk — the therapeutic range for atrial fibrillation is 2.0 to 3.0; failing to act on an INR of 5.8 is clinically inappropriate regardless of patient age.
• Option C: Option C is incorrect; discontinuing fluconazole prematurely sacrifices treatment efficacy unnecessarily when the interaction is manageable with warfarin dose adjustment; topical therapy alone may be insufficient for the duration and severity of infection after a partially completed course.
• Option D: Option D is incorrect; dietary vitamin K changes do not typically cause INR elevations of this magnitude in isolation, and the temporal correlation with fluconazole initiation three weeks ago strongly points to the CYP2C9-mediated drug interaction as the cause; increasing the warfarin dose in the face of an INR of 5.8 would be dangerous.

ANSWER: B

Rationale:

Option B is correct. Midazolam is one of the most CYP3A4-dependent benzodiazepines in clinical use — it is cleared almost entirely by CYP3A4-mediated hydroxylation to 1-hydroxymidazolam, which is subsequently glucuronidated. At a steady-state continuous infusion, midazolam plasma concentrations are directly proportional to the infusion rate divided by the clearance rate. When voriconazole — a potent CYP3A4 inhibitor — is introduced, midazolam clearance falls substantially; at an unchanged infusion rate, plasma concentrations rise progressively as the new, lower clearance steady state is reached. The clinical consequence is deepened sedation and, at high enough concentrations, respiratory depression. This interaction is particularly relevant in mechanically ventilated ICU patients because the consequences of excess sedation include prolonged mechanical ventilation, ICU-acquired weakness, delayed weaning, and ventilator-associated pneumonia. The correct management is to reduce the midazolam infusion rate substantially — approximately by 50% is a reasonable starting point, with titration guided by the RASS target — while continuing voriconazole at full therapeutic doses for the aspergillosis. Other CYP3A4-dependent opioids commonly used in ICU sedation, including fentanyl and alfentanil, are similarly affected by voriconazole.

• Option A: Option A is incorrect; while CNS aspergillosis can cause encephalopathy, the temporal correlation — deepening sedation beginning within hours of voriconazole initiation at an unchanged midazolam rate — points directly to the CYP3A4-mediated pharmacokinetic interaction; voriconazole does affect midazolam pharmacokinetics through CYP3A4 inhibition.
• Option C: Option C is incorrect; the interaction is pharmacokinetic, not pharmacodynamic — it is not a receptor-level synergism but rather voriconazole-driven accumulation of midazolam at the same infusion rate; dose reduction of midazolam does correct the problem by restoring the concentration-clearance balance; flumazenil reversal is appropriate for acute life-threatening respiratory depression but is not the primary management of a predictable pharmacokinetic interaction.
• Option D: Option D is incorrect; voriconazole is a CYP3A4 inhibitor, not an inducer — it does not upregulate CYP3A4 through pregnane X receptor activation; the reduction in midazolam clearance is due to enzyme inhibition.
• Option E: Option E is incorrect; midazolam does compete for CYP3A4, but the primary pharmacokinetic consequence of the interaction is voriconazole's inhibition of midazolam clearance causing midazolam accumulation — the reverse direction (midazolam reducing voriconazole) is a minor secondary effect; discontinuing midazolam entirely is not the correct approach when dose reduction achieves the clinical goal.

ANSWER: D

Rationale:

Option D is correct. The voriconazole-phenytoin interaction is bidirectional and both directions are operating simultaneously in this patient, producing the characteristic paired laboratory abnormalities. In the first direction, phenytoin is a potent inducer of CYP2C19 and CYP2C9 — the two primary enzymes responsible for voriconazole metabolism. Induction of these enzymes accelerates voriconazole breakdown, reducing plasma concentrations by approximately 70% below those expected at standard doses. The voriconazole trough of 0.4 mg/L confirms subtherapeutic exposure despite apparently adequate dosing. In the second direction, voriconazole is a potent CYP2C9 inhibitor, and phenytoin is metabolized primarily by CYP2C9 to its inactive 5-(4-hydroxyphenyl) metabolite. Inhibition of CYP2C9 slows phenytoin clearance, causing phenytoin to accumulate — here to 28 mcg/mL, which is above the therapeutic range of 10 to 20 mcg/mL and producing classic signs of phenytoin toxicity: diplopia (a common early phenytoin toxic effect from cerebellar and vestibular effects) and ataxia. Both directions require urgent simultaneous management. The voriconazole maintenance dose must be doubled to 400 mg oral twice daily or 8 mg/kg intravenously twice daily to overcome the induction effect, with TDM repeated at Day 5 to 7 of the new dose. Phenytoin must be dose-reduced with close monitoring of phenytoin levels to prevent worsening toxicity while ensuring antiepileptic efficacy is maintained. If adequate voriconazole trough concentrations cannot be achieved despite dose doubling with concurrent phenytoin, transitioning phenytoin to an antiepileptic drug not dependent on CYP2C9 for metabolism — such as levetiracetam or valproate — should be strongly considered.

• Option A: Option A is incorrect; the two laboratory findings are mechanistically linked by the bidirectional pharmacokinetic interaction and should not be investigated as independent unrelated findings — this interpretation would delay treatment of both the subtherapeutic antifungal exposure and the phenytoin toxicity.
• Option B: Option B is incorrect; the two abnormalities do not result from a single sequential mechanism — each direction of the interaction is independent, and reducing phenytoin alone does not correct voriconazole's subtherapeutic trough, which requires dose escalation to overcome the induction effect.
• Option C: Option C is incorrect; voriconazole is not metabolized to a phenytoin-like neurotoxic compound — the diplopia and ataxia are characteristic signs of phenytoin toxicity at supratherapeutic concentrations, not voriconazole metabolite effects.
• Option E: Option E is incorrect; phenytoin does induce CYP2C9 in addition to CYP2C19, and this induction contributes to voriconazole's reduced clearance; dismissing the phenytoin supratherapeutic level as unrelated ignores the CYP2C9-mediated voriconazole inhibition of phenytoin clearance that is directly causing phenytoin accumulation.

ANSWER: C

Rationale:

Option C is correct. This case illustrates one of the most preventable causes of acute rejection in transplant patients receiving azole antifungal therapy — failure to proactively manage the CYP3A4 inhibition reversal at azole discontinuation. During the 12-week voriconazole course, the tacrolimus dose had been reduced to 0.5 mg twice daily to compensate for voriconazole's approximately 3- to 5-fold elevation of tacrolimus exposure through CYP3A4 inhibition. This dose was specifically calibrated for the inhibited clearance state — it produced therapeutic troughs of 7 ng/mL only because voriconazole was simultaneously raising tacrolimus concentrations by slowing its metabolism. When voriconazole was discontinued, CYP3A4 inhibition resolved over the following two to five days as voriconazole was cleared. Tacrolimus clearance then normalized to its pre-voriconazole baseline, and the 0.5 mg twice daily dose — which had been adequate with inhibited clearance — became substantially insufficient as clearance recovered. Tacrolimus concentrations fell progressively over days to the subtherapeutic trough of 2.1 ng/mL, far below the levels required for adequate alloimmune suppression. The resulting immunological window allowed T-cell-mediated acute cellular rejection to develop and manifest clinically by Day 8. The correct management at azole discontinuation was to proactively increase tacrolimus toward the pre-voriconazole dose (approximately 1 to 2 mg twice daily as the starting reference) and measure daily trough levels for five to seven days to guide adjustment — a protocol that was not followed.

• Option A: Option A is incorrect; voriconazole has no immunostimulatory mechanism that directly drives rejection on withdrawal — it is an antifungal agent without relevant T-cell-activating properties; the rejection is entirely explained by subtherapeutic tacrolimus.
• Option B: Option B is incorrect; while severe acute rejection does impair hepatic function and can secondarily reduce tacrolimus metabolism, the sequence here is clear — tacrolimus fell to subtherapeutic levels because of voriconazole discontinuation without dose adjustment, precipitating rejection; the hepatic dysfunction is a consequence of rejection, not its primary cause.
• Option D: Option D is incorrect; voriconazole does not suppress T regulatory cells or produce persistent immunological changes after discontinuation — its pharmacological effects are metabolic enzyme inhibition and antifungal activity; adjusting the tacrolimus dose to therapeutic troughs is the correct management.
• Option E: Option E is incorrect; a tacrolimus trough of 2.1 ng/mL is subtherapeutic for a liver transplant recipient at any post-transplant time point where immunosuppression is active — most centers maintain troughs of 5 to 10 ng/mL or higher in the first year; dismissing the trough as acceptable contradicts the biopsy-confirmed acute rejection that it caused.

ANSWER: A

Rationale:

Option A is correct. Ritonavir's primary pharmacological role as a pharmacokinetic booster in combination antiretroviral regimens is based on its potent CYP3A4 inhibitory activity — even at the low boosting doses used (100 to 200 mg daily), ritonavir produces substantial CYP3A4 inhibition that raises co-administered protease inhibitor concentrations. Isavuconazole is a CYP3A4 substrate, meaning it is susceptible to CYP3A4 inhibition by ritonavir. When lopinavir/ritonavir is co-administered with isavuconazole, ritonavir's CYP3A4 inhibition reduces isavuconazole clearance and raises its plasma concentrations above those expected from the standard isavuconazole dose. The magnitude of this increase means that supratherapeutic isavuconazole concentrations are possible, with associated risks of hepatotoxicity and other adverse effects. While there is currently no established therapeutic trough range for isavuconazole TDM in routine practice, the presence of a potent CYP3A4 inhibitor in the regimen is one of the situational indications where isavuconazole TDM is warranted — as the prescribing information and clinical guidance documents acknowledge. Clinicians should monitor for isavuconazole-associated adverse effects and consider TDM to guide management if toxicity or treatment failure occurs.

• Option B: Option B is incorrect; the relevant interaction mechanism is CYP3A4 inhibition by ritonavir, not OATP transporter inhibition by lopinavir; the direction of the interaction is rising isavuconazole concentrations, not falling concentrations requiring dose escalation.
• Option C: Option C is incorrect; ritonavir is a CYP3A4 inhibitor at clinical doses, not an inducer; at very high non-clinical doses some CYP induction has been observed, but at the pharmacokinetic boosting doses used in clinical practice, ritonavir inhibits CYP3A4 and raises CYP3A4 substrate concentrations — it does not mimic the rifampin interaction.
• Option D: Option D is incorrect; isavuconazole does not inhibit the protease enzyme activity of lopinavir — it is an antifungal azole with CYP enzyme inhibitory activity, not a protease inhibitor itself; there is no pharmacological basis for isavuconazole reducing antiretroviral protease inhibitor activity.
• Option E: Option E is incorrect; isavuconazole is metabolized by CYP3A4, making it susceptible to CYP3A4 inhibition by ritonavir; the claim that it is eliminated primarily by non-CYP pathways and has no interaction with ritonavir is pharmacologically inaccurate.

ANSWER: E

Rationale:

Option E is correct. Micafungin's pharmacokinetic interaction profile with calcineurin inhibitors is one of its most clinically important advantages over azole antifungals in transplant recipients. Unlike voriconazole, posaconazole, and itraconazole — which are potent CYP3A4 inhibitors that produce 2- to 5-fold rises in tacrolimus area under the concentration-time curve requiring proactive dose reduction and intensive monitoring — micafungin does not significantly inhibit CYP3A4, CYP2C9, or CYP2C19 at clinical concentrations. Clinical pharmacokinetic studies examining micafungin-tacrolimus co-administration have not found a meaningful interaction requiring routine dose adjustment. Tacrolimus can therefore be continued at its current dose when micafungin is initiated, and monitoring frequency does not need to be increased from standard transplant protocols. This favorable profile, along with the absence of a significant interaction with cyclosporine or sirolimus, is why micafungin and anidulafungin are the pharmacokinetically preferred echinocandins for candidemia in transplant patients on complex immunosuppressive regimens. The resident's instinct to apply azole-interaction protocols to micafungin is understandable but incorrect — the interaction principles differ fundamentally between drug classes, and class-level assumptions about antifungal interactions lead to unnecessary dose changes.

• Option A: Option A is incorrect; micafungin is not a CYP3A4 inhibitor of equivalent potency to voriconazole — it does not have meaningful CYP3A4 inhibitory activity at clinical doses, and no tacrolimus dose reduction is required.
• Option B: Option B is incorrect; the requirement for tacrolimus dose reduction is not a universal antifungal protocol — it is specific to drugs that inhibit CYP3A4 or other pathways relevant to tacrolimus metabolism; blanket application of this rule to all antifungals would result in unnecessary and potentially harmful dose reductions.
• Option C: Option C is incorrect; micafungin does not significantly inhibit P-glycoprotein at clinical concentrations in a manner that raises tacrolimus absorption; this is not the mechanism of the echinocandin-tacrolimus interaction.
• Option D: Option D is incorrect; micafungin is not metabolized by CYP3A4 — it undergoes arylsulfatase-mediated and catechol-O-methyltransferase-mediated metabolism; it is not a CYP3A4 substrate and does not competitively inhibit tacrolimus CYP3A4 metabolism.

ANSWER: B

Rationale:

Option B is correct. Fluconazole's pharmacokinetic profile makes it uniquely sensitive to renal impairment among the azole antifungals: approximately 80% of a fluconazole dose is excreted unchanged in urine, meaning that the kidneys are the primary elimination route and renal function directly determines clearance. At a creatinine clearance of 25 mL/min — well below the 50 mL/min threshold at which dose reduction is required — fluconazole clearance is severely impaired, and standard doses produce steady-state concentrations substantially higher than in patients with normal renal function. The resulting accumulation at 400 mg daily can produce concentration-dependent adverse effects including hepatotoxicity (elevated transaminases), gastrointestinal toxicity (nausea, vomiting), and potentially worsened renal function. The correct prescribing approach is to halve the maintenance dose to 200 mg daily when creatinine clearance falls below 50 mL/min, with the standard loading dose retained at 400 mg (or higher for esophageal candidiasis in some guidelines) since the loading dose is determined by volume of distribution, not clearance. Patients on dialysis require supplemental dosing after each hemodialysis session. Current management should include dose reduction or temporary hold depending on the severity of toxicity, close monitoring of creatinine and liver enzymes, and resumption at the renal-adjusted dose once the patient is stable.

• Option A: Option A is incorrect; fluconazole is not primarily hepatically metabolized — it is approximately 80% renally eliminated as unchanged drug; renal function directly and substantially affects its clearance, and dose adjustment in renal impairment is a mandatory component of fluconazole prescribing.
• Option C: Option C is incorrect; fluconazole does not generate hepatotoxic metabolites through CYP2C19 in a clinically meaningful manner — the liver enzyme elevation here reflects systemic drug accumulation from impaired renal elimination, not metabolite accumulation in hepatic tissue; switching antifungals would be appropriate if toxicity cannot be managed by dose adjustment, and accumulated fluconazole would clear once the drug is held.
• Option D: Option D is incorrect; direct nephrotoxicity is a characteristic of amphotericin B formulations, not fluconazole — fluconazole does not cause direct tubular necrosis; the creatinine rise in this case more likely reflects pre-existing renal disease compounded by drug accumulation effects rather than direct azole nephrotoxicity.
• Option E: Option E is incorrect; fluconazole accumulation in renal impairment is due to reduced renal excretion of the unchanged drug, not hepatic CYP2C19 saturation; a 75% dose reduction is excessive and unsupported by pharmacokinetic guidance, which recommends 50% dose reduction for creatinine clearance below 50 mL/min.

ANSWER: D

Rationale:

Option D is correct. This case demonstrates two concurrent and compounding itraconazole capsule absorption errors. The first error is pantoprazole co-administration: itraconazole capsules depend on low gastric pH for dissolution — the drug is a weakly basic lipophilic molecule that ionizes and dissolves more readily under acidic conditions. Pantoprazole (a proton pump inhibitor) raises intragastric pH, impairing this dissolution step and reducing itraconazole capsule bioavailability substantially, typically by 40 to 60% compared to conditions with normal gastric acidity. The second error is fasting administration: itraconazole capsule absorption is significantly enhanced by co-ingestion of a high-fat meal, which stimulates bile secretion, promotes micellar solubilization of the lipophilic drug, and facilitates lymphatic absorption; taking capsules before breakfast on an empty stomach removes this enhancement and can reduce bioavailability by approximately 40 to 50% compared to fed-state administration. The combination of both errors — acid suppression and fasting — produces multiplicative absorption failure that explains the trough of 0.25 mg/L despite adherence. The correct approach is to address both factors: discontinue or substitute the pantoprazole if clinically safe, instruct the patient to take capsules with a full meal, and consider switching to the itraconazole oral solution (which is formulated in hydroxypropyl-beta-cyclodextrin, does not depend on gastric pH, and is actually best taken on an empty stomach — the opposite of the capsule).

• Option A: Option A is incorrect; itraconazole is not preferentially absorbed in the colon, and inflammatory bowel disease is not established in this patient; the absorption site is the upper gastrointestinal tract, and the specific pharmacokinetic barriers are pH and fat intake, not colonic pathology.
• Option B: Option B is incorrect; pantoprazole does not upregulate intestinal CYP3A4 through PXR activation in a clinically significant way — its primary effect relevant to itraconazole is acid suppression impairing dissolution; adding a CYP3A4 inhibitor to address this would not correct the absorption problem and introduces additional interaction risks.
• Option C: Option C is incorrect; while Histoplasma resistance to itraconazole does occur, the first investigation in a patient with documented subtherapeutic troughs despite adherence should address the pharmacokinetic factors before assuming resistance; the specific administration errors identified here are the more parsimonious explanation for the treatment failure.
• Option E: Option E is incorrect; itraconazole is metabolized primarily by CYP3A4, not CYP2C19, and CYP2C19 ultrarapid metabolizer status does not significantly affect itraconazole pharmacokinetics; the subtherapeutic trough is explained by absorption failure, not by accelerated CYP2C19-mediated metabolism.

ANSWER: C

Rationale:

Option C is correct. A subtherapeutic voriconazole trough at Day 7 in the absence of known CYP enzyme inducers warrants structured investigation before empiric dose doubling, for two important reasons. First, the CYP2C19 ultrarapid metabolizer (UM) phenotype — caused by gene duplication or gain-of-function alleles producing high CYP2C19 activity — causes rapid voriconazole clearance that can produce subtherapeutic troughs at standard doses even without any interacting drug. UM phenotype is the pharmacogenomic explanation for this clinical picture, and if confirmed, dose escalation is clearly indicated and expected to be effective because the enzyme is functioning rapidly but is not saturated. Knowing the genotype guides the dose increment chosen and sets expectations for the new target. Second, although nursing-reported adherence is reassuring, undisclosed partial non-adherence cannot be completely excluded; in a CYP2C19 normal metabolizer with partial adherence, doubling the dose would produce supratherapeutic concentrations and potential toxicity if the patient subsequently becomes fully adherent or if adherence was consistently partial rather than absent. The attending's structured approach — obtaining CYP2C19 genotype, reviewing pharmacy dispensing records, and confirming the clinical picture before committing to a doubling — is pharmacologically sound and prevents both underdosing the UM patient and overtoxifying the non-adherent normal metabolizer. In practice, dose escalation should not be indefinitely delayed when a patient has invasive aspergillosis; if genotyping is not immediately available, a modest dose increase with repeat TDM at Day 5 to 7 of the new dose is a reasonable middle path.

• Option A: Option A is incorrect; a voriconazole trough of 0.6 mg/L is subtherapeutic — it is below the established efficacy threshold of 1.0 mg/L, and published clinical data associate troughs below 1.0 to 1.5 mg/L with increased rates of treatment failure in invasive aspergillosis; no dose change is not an appropriate response.
• Option B: Option B is incorrect; Aspergillus-produced toxins inactivating voriconazole in vivo is not an established mechanism of treatment failure — drug resistance in Aspergillus is mediated by target enzyme mutations (CYP51A), not by voriconazole inactivation; susceptibility testing is important but does not precede investigation of the patient's pharmacokinetic profile when a pharmacokinetic explanation is available.
• Option D: Option D is incorrect; voriconazole oral bioavailability is approximately 96% — among the highest of any oral antifungal agent — and is not the limiting factor in this case; switching to intravenous formulation would produce essentially equivalent plasma concentrations at the same dose and does not address the underlying clearance issue.
• Option E: Option E is incorrect; voriconazole reaches steady state within five to seven days of consistent twice-daily dosing when a loading dose has been administered; a Day 7 trough represents true maintenance steady state and is the correct timepoint for the first TDM sample; waiting until Day 14 would delay necessary management by another week during active treatment of invasive aspergillosis.